Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III prospective, randomized, double-blind, placebo-controlled, multi-centred tolerance and efficacy study of RSD1235 [vernakalant; Kynapid] in patients with atrial fibrillation

Next Previous
X
Search
Trial Profile

A phase III prospective, randomized, double-blind, placebo-controlled, multi-centred tolerance and efficacy study of RSD1235 [vernakalant; Kynapid] in patients with atrial fibrillation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Registrational; Therapeutic Use
  • Acronyms ACT-I
  • Sponsors Correvio Pharma

    • Most Recent Events

    • 02 Sep 2010 Vernakalant has been approved in the EU, Iceland and Norway based on the results of ACT-I, -II and -III and AVRO trials, according to a Merck media release.
    • 25 Mar 2008 Results have been published (801080480).
    • 09 May 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top